These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17043169)

  • 1. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice.
    Steffens S; Burger F; Pelli G; Dean Y; Elson G; Kosco-Vilbois M; Chatenoud L; Mach F
    Circulation; 2006 Oct; 114(18):1977-84. PubMed ID: 17043169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice.
    Sasaki N; Yamashita T; Takeda M; Shinohara M; Nakajima K; Tawa H; Usui T; Hirata K
    Circulation; 2009 Nov; 120(20):1996-2005. PubMed ID: 19884470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis.
    van Puijvelde GH; Hauer AD; de Vos P; van den Heuvel R; van Herwijnen MJ; van der Zee R; van Eden W; van Berkel TJ; Kuiper J
    Circulation; 2006 Oct; 114(18):1968-76. PubMed ID: 17060383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD3 antibody treatment stimulates the functional capability of regulatory T cells.
    Chatenoud L
    Novartis Found Symp; 2003; 252():279-86; discussion 286-90. PubMed ID: 14609225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis.
    van Puijvelde GH; van Es T; van Wanrooij EJ; Habets KL; de Vos P; van der Zee R; van Eden W; van Berkel TJ; Kuiper J
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2677-83. PubMed ID: 17901374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis.
    Dinh TN; Kyaw TS; Kanellakis P; To K; Tipping P; Toh BH; Bobik A; Agrotis A
    Circulation; 2012 Sep; 126(10):1256-66. PubMed ID: 22851544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells.
    Chen G; Han G; Wang J; Wang R; Xu R; Shen B; Qian J; Li Y
    J Leukoc Biol; 2008 Feb; 83(2):280-7. PubMed ID: 18029395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.
    You S; Leforban B; Garcia C; Bach JF; Bluestone JA; Chatenoud L
    Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6335-40. PubMed ID: 17389382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells.
    Perruche S; Zhang P; Liu Y; Saas P; Bluestone JA; Chen W
    Nat Med; 2008 May; 14(5):528-35. PubMed ID: 18438416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.
    Belghith M; Bluestone JA; Barriot S; Mégret J; Bach JF; Chatenoud L
    Nat Med; 2003 Sep; 9(9):1202-8. PubMed ID: 12937416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice.
    Buono C; Pang H; Uchida Y; Libby P; Sharpe AH; Lichtman AH
    Circulation; 2004 Apr; 109(16):2009-15. PubMed ID: 15096453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of atherosclerosis with anti-CD3 antibody via augmenting a regulatory T-cell response in mice.
    Kita T; Yamashita T; Sasaki N; Kasahara K; Sasaki Y; Yodoi K; Takeda M; Nakajima K; Hirata K
    Cardiovasc Res; 2014 Apr; 102(1):107-17. PubMed ID: 24403315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T cells ameliorate hyperhomocysteinaemia-accelerated atherosclerosis in apoE-/- mice.
    Feng J; Zhang Z; Kong W; Liu B; Xu Q; Wang X
    Cardiovasc Res; 2009 Oct; 84(1):155-63. PubMed ID: 19502284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis.
    Taleb S; Herbin O; Ait-Oufella H; Verreth W; Gourdy P; Barateau V; Merval R; Esposito B; Clément K; Holvoet P; Tedgui A; Mallat Z
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2691-8. PubMed ID: 17690315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion of apoptotic beta-cells induces immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice.
    Xia CQ; Peng R; Qiu Y; Annamalai M; Gordon D; Clare-Salzler MJ
    Diabetes; 2007 Aug; 56(8):2116-23. PubMed ID: 17496235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
    Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
    Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
    Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
    Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney.
    Zhang JL; Sun DJ; Hou CM; Wei YL; Li XY; Yu ZY; Feng JN; Shen BF; Li Y; Xiao H
    Transpl Immunol; 2010 Oct; 24(1):17-25. PubMed ID: 20850528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
    Thorp E; Kuriakose G; Shah YM; Gonzalez FJ; Tabas I
    Circulation; 2007 Nov; 116(19):2182-90. PubMed ID: 17967777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
    Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.